Investors should monitor crucial support levels on the S&P 500's chart around 5,445 and 5,260, while also watching key resistance levels near 5,875 and 6,090. The S&P 500 (SPX) lost ground last ...

The last time I wrote about Dyne Therapeutics (NASDAQ:DYN) it was with respect to a Seeking Alpha article entitled "Dyne: H2 2024 Muscle Disease Data Could Boost Value". In this article ...

WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...

March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven ...

Dyne Therapeutics (DYN) announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement at the selected ...

Currently, the analyst consensus on Dyne Therapeutics is a Strong Buy with an average price target of $51.44, which is a 326.89% upside from current levels. In a report released today, Piper ...

The depth chart is looking pretty respectable though, as long as you're willing to overlook the whole offensive line thing. The Seahawks certainly have. Anyway, let's see if we can project what ...